Previous 10 | Next 10 |
Takeda Pharmaceutical Company Limited (TKPHF) Q4 2019 Earnings Conference Call May 13, 2020, 08:30 AM ET Company Participants Takashi Okubo - IR Christophe Weber - President and CEO Andrew Plump - President of R&D Costa Saroukos - CFO Ramona Sequeira - President of USBU a...
Exelixis (NASDAQ: EXEL) and bluebird bio (NASDAQ: BLUE) are two biotech companies that have been moving in opposite directions on the stock market this year. While Exelixis has provided healthy gains -- its stock is up by 52.1% year to date -- Bluebird's shares have slid by 35.2% since t...
SIFCO (NYSEMKT: SIF ) +61% on Q2 results . More news on: SIFCO Industries, Inc., United Natural Foods, Inc., Cyclacel Pharmaceuticals, Inc., Stocks on the move, , Read more ...
The following slide deck was published by Takeda Pharmaceutical Company Limited in conjunction with their 2019 Q4 earnings Read more ...
Takeda Pharmaceutical Company Limited (TOKYO: 4502) (NYSE: TAK) (“Takeda”) today announced financial results for the year ended March 31, 2020 (FY2019). As a top 10 global R&D-driven biopharmaceutical company, Takeda is demonstrating its innovation and values in its respon...
Quick Take ADC Therapeutics ( ADCT ) intends to raise $125 million from the sale of its common stock, per an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of blood cancers and solid tumors. ADCT is making a new attempt to go pu...
Protalix BioTherapeutics (NYSEMKT: PLX ) announces positive results from a Phase 3 clinical trial, BRIDGE , evaluating enzyme replacement therapy pegunigalsidase alfa (PLX-102) in Fabry disease patients who previously received Takeda's (NYSE: TAK ) Replagal (agalsidase alfa). More news ...
The European Commission has granted Takeda Pharmaceutical (NYSE: TAK ) a Marketing Authorization for the subcutaneous (SC) formulation of Entyvio (vedolizumab), a gut-selective biologic for use as maintenance therapy in adults with moderately to severely active ulcerative colitis (UC)...
− Approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease − Additional treatment modality provides more options for how pa...
OSAKA, Japan , and KING OF PRUSSIA, Pa. , May 7, 2020 /PRNewswire/ -- The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19, is rapidly building...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection Canada NewsWire The Letter of Intent is an important ste...
Wednesday, Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) dengue vaccine received World Health Organization’s (WHO) preq...
Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill. Takeda’s presentations will spa...